Acorda cashes out on Ampyra royalties

Acorda Therapeutics Inc. (NASDAQ:ACOR) granted HealthCare Royalty Partners (Stamford, Conn.) rights to royalty revenue for Ampyra dalfampridine (BIIB041), up to an undisclosed threshold, for $40 million. Acorda gained the royalties under a 2009 deal with Biogen Inc. (NASDAQ:BIIB), in which Biogen agreed to pay up to $400 million in milestones for ex-U.S. rights to the candidate (see BioCentury, July 6, 2009)...